Bioinformatics_NNS and_CC Clinical_JJ Informatics_NNS --_: The_DT Imperative_NN to_TO Collaborate_JJ null_NN In_IN less_JJR than_IN a_DT decade_NN ,_, the_DT Human_NP Genome_NP project_NN (_( HGP_NP )_) has_VBZ generated_VBN a_DT large_JJ amount_NN of_IN biological_JJ data_NNS that_WDT is_VBZ likely_JJ eventually_RB to_TO lead_VB to_TO a_DT qualitative_JJ change_NN in_IN the_DT way_NN in_IN which_WDT clinical_JJ medicine_NN (_( diagnostics_NNS ,_, prognostics_NNS ,_, and_CC therapeutics_NNS )_) is_VBZ practiced_VBN ._SENT A_DT central_JJ intellectual_JJ and_CC technologic_JJ asset_NN to_TO this_DT effort_NN has_VBZ been_VBN GenBank_NP and_CC related_JJ genomic_NN and_CC protein_NN databases_NNS (_( e.g._FW ,_, the_DT SWISS-PROT_NP ,_, Exon-Intron_NP ,_, and_CC IMGT_NP databases_NNS )_) ._SENT Their_PP$ standardized_JJ data_NNS models_NNS have_VBP allowed_VBN research_NN laboratories_NNS throughout_IN the_DT world_NN to_TO rapidly_RB populate_VB them_PP with_IN the_DT very_RB latest_JJS information_NN ._SENT In_IN turn_NN ,_, these_DT databases_NNS are_VBP freely_RB available_JJ throughout_IN the_DT world_NN via_IN the_DT Internet_NN and_CC have_VBP seeded_VBN ,_, accelerated_VBD ,_, and_CC inspired_VBD thousands_NNS of_IN research_NN projects_NNS ._SENT In_IN contrast_NN ,_, there_EX are_VBP few_JJ ,_, if_IN any_DT ,_, consequential_JJ shared_JJ national_JJ clinical_JJ databases_NNS ._SENT Specifically_RB ,_, patient_JJ data_NNS in_IN one_CD information_NN system_NN can_MD only_RB rarely_RB be_VB transferred_VBN to_TO another_DT to_TO expedite_VB patient_JJ care_NN ._SENT This_DT ,_, despite_IN decades_NNS of_IN research_NN and_CC development_NN of_IN clinical_JJ record_NN systems_NNS ._SENT This_DT marked_JJ contrast_NN is_VBZ deceptive_JJ ._SENT The_DT HGP_NP has_VBZ benefited_VBN from_IN the_DT elegant_JJ simplicity_NN of_IN the_DT genetic_JJ code_NN ._SENT In_IN essence_NN ,_, at_IN the_DT level_NN of_IN primary_JJ structure_NN ,_, the_DT genetic_JJ information_NN coded_VBN by_IN any_DT organism_NN is_VBZ simply_RB a_DT sequence_NN of_IN characters_NNS drawn_VBN from_IN a_DT very_RB limited_JJ alphabet_NN ._SENT Consequently_RB ,_, there_EX are_VBP only_RB a_DT very_RB few_JJ items_NNS that_WDT GenBank_NP requires_VBZ be_VB submitted_VBN for_IN an_DT entry_NN to_TO be_VB a_DT valid_JJ (_( and_CC useful_JJ )_) component_NN of_IN its_PP$ database_NN ._SENT The_DT clinical_JJ care_NN of_IN human_JJ beings_NNS is_VBZ far_RB more_RBR complex_JJ ,_, requiring_VBG at_IN the_DT minimum_NN a_DT detailed_JJ record_NN of_IN the_DT history_NN of_IN multiple_JJ clinical_JJ interventions_NNS and_CC outcomes_NNS ,_, relevant_JJ life_NN history_NN ,_, and_CC clinical_JJ measurements_NNS that_WDT span_VBP several_JJ modalities_NNS ,_, from_IN serum_NN chemistry_NN to_TO brain_NN imaging_NN ._SENT It_PP is_VBZ not_RB surprising_JJ that_IN the_DT data_NNS model_NN required_VBN to_TO capture_VB all_PDT this_DT information_NN is_VBZ extremely_RB complex_JJ ,_, as_RB is_VBZ evidenced_VBN by_IN the_DT Health_NP Level_NP 7_CD Reference_NP Information_NP Model_NP ._SENT It_PP is_VBZ a_DT remarkable_JJ tribute_NN to_TO the_DT persistence_NN of_IN the_DT individuals_NNS involved_VBN in_IN these_DT standardization_NN efforts_NNS ,_, that_WDT they_PP have_VBP been_VBN able_JJ to_TO arrive_VB at_IN a_DT reasonably_RB adequate_JJ standardized_JJ representation_NN of_IN not_RB only_RB the_DT many_JJ descriptors_NNS but_CC much_RB of_IN the_DT process_NN and_CC business_NN of_IN clinical_JJ care_NN ._SENT As_IN the_DT HGP_NP moves_NNS from_IN the_DT acquisition_NN of_IN raw_JJ genomics_NNS data_NNS to_TO the_DT biological_JJ function_NN of_IN the_DT discovered_VBN genes_NNS and_CC their_PP$ clinical_JJ importance_NN ,_, the_DT bioinformatics_NN community_NN will_MD have_VB to_TO address_VB very_RB similar_JJ complexities_NNS ._SENT That_DT is_VBZ ,_, the_DT clinical_JJ annotation_NN of_IN genomic_JJ data_NNS sets_NNS ,_, particularly_RB for_IN human_JJ beings_NNS ,_, will_MD essentially_RB provide_VB the_DT equivalent_NN ,_, if_IN not_RB identical_JJ ,_, challenge_NN of_IN the_DT creation_NN of_IN a_DT comprehensive_JJ medical_JJ record_NN ._SENT Even_RB prior_RB to_TO encompassing_VBG the_DT entirety_NN of_IN clinical_JJ annotation_NN ,_, the_DT genomics_NN community_NN has_VBZ faltered_VBN in_IN developing_VBG shared_JJ and_CC standardized_JJ data_NN models_NNS where_WRB the_DT simplicity_NN of_IN the_DT genome_NN no_RB longer_RBR dominates_VBZ ._SENT For_IN example_NN ,_, there_EX are_VBP several_JJ competing_VBG technologies_NNS for_IN the_DT massively_RB parallel_JJ measurement_NN of_IN gene_NN expression_NN using_VBG microarrays_NNS ._SENT Some_DT of_IN these_DT arrays_NNS use_VBP two_CD probes_NNS per_IN gene_NN and_CC are_VBP constructed_VBN using_VBG robotic_JJ spotting_VBG techniques_NNS ._SENT Others_NNS are_VBP constructed_VBN with_IN oligonucleotides_NNS using_VBG photolithographic_JJ techniques_NNS ._SENT Although_IN all_PDT these_DT techniques_NNS measure_NN gene_NN expression_NN ,_, a_DT widely_RB adopted_VBN standard_NN to_TO represent_VB the_DT results_NNS across_IN all_DT microarray_NN technologies_NNS has_VBZ yet_RB to_TO emerge_VB ._SENT The_DT GATC_NP proposal_NN ,_, for_IN example_NN ,_, is_VBZ a_DT possible_JJ candidate_NN for_IN such_PDT a_DT data_NNS model_NN ,_, but_CC its_PP$ usage_NN is_VBZ currently_RB spotty_JJ and_CC controversial_JJ ._SENT To_TO clinical_JJ informaticians_NNS ,_, this_DT will_MD be_VB all_DT too_RB reminiscent_JJ of_IN the_DT challenge_NN of_IN creating_VBG a_DT shared_JJ data_NN model_NN for_IN laboratory_NN results_NNS ._SENT The_DT lack_NN of_IN widely_RB accepted_VBN standardized_JJ vocabularies_NNS for_IN clinical_JJ care_NN has_VBZ greatly_RB hampered_VBN the_DT development_NN of_IN automated_JJ decision_NN support_NN tools_NNS and_CC clinical_JJ research_NN databases_NNS ._SENT The_DT impossibility_NN of_IN guaranteeing_VBG that_IN a_DT serum_NN sodium_NN or_CC systolic_JJ blood_NN pressure_NN has_VBZ the_DT same_JJ code_NN or_CC term_NN throughout_IN our_PP$ hospital_NN system_NN is_VBZ troublesome_JJ ._SENT Fortunately_RB ,_, several_JJ efforts_NNS in_IN the_DT private_JJ and_CC public_JJ realm_NN (_( e.g._FW ,_, LOINC_NP )_) are_VBP addressing_VBG this_DT issue_NN ._SENT The_DT National_NP Library_NP of_IN Medicine_NP has_VBZ invested_VBN large_JJ resources_NNS to_TO enable_VB these_DT different_JJ vocabularies_NNS to_TO be_VB interoperable_JJ ,_, at_IN least_JJS at_IN a_DT basic_JJ level_NN ._SENT The_DT same_JJ problems_NNS are_VBP not_RB unknown_JJ in_IN bioinformatics_NNS ._SENT Even_RB at_IN this_DT early_JJ stage_NN of_IN the_DT HGP_NP ,_, DNA_NN sequences_NNS that_WDT were_VBD previously_RB not_RB known_VBN to_TO be_VB part_NN of_IN the_DT same_JJ gene_NN have_VBP different_JJ names_NNS and_CC are_VBP joined_VBN in_IN only_RB some_DT databases_NNS (_( with_IN varying_VBG levels_NNS of_IN confidence_NN )_) ._SENT As_IN the_DT HGP_NP ventures_NNS into_IN diverse_JJ areas_NNS of_IN bioscience_NN (_( as_RB well_RB as_IN into_IN the_DT clinical_JJ area_NN )_) ,_, vocabulary_NN issues_NNS are_VBP also_RB important_JJ ._SENT Indeed_RB ,_, the_DT lack_NN of_IN a_DT standardized_JJ vocabulary_NN already_RB arises_VBZ in_IN genomics_NNS as_IN well_RB ,_, in_IN annotations_NNS ._SENT For_IN example_NN ,_, despite_IN the_DT fact_NN that_IN the_DT basic_JJ data_NN element_NN of_IN GenBank_NP is_VBZ the_DT sequence_NN (_( which_WDT has_VBZ an_DT easily_RB standardized_JJ representation_NN )_) ,_, there_EX are_VBP diverse_JJ annotations_NNS that_WDT are_VBP very_RB nonstandardized_VBN right_RB now_RB ._SENT A_DT recent_JJ report_NN by_IN the_DT Institute_NP of_IN Medicine_NP highlights_VBZ the_DT immense_JJ mortality_NN and_CC morbidity_NN due_JJ to_TO medical_JJ errors_NNS ._SENT Clinical_JJ informaticians_NNS (_( e.g._FW ,_, Bates_NP et_FW al._FW and_CC Kuperman_NP et_FW al._FW ,_, )_) have_VBP been_VBN instrumental_JJ in_IN demonstrating_VBG how_WRB automated_JJ systems_NNS can_MD be_VB used_VBN to_TO reduce_VB this_DT error_NN rate_NN ._SENT These_DT industrial_JJ processing_NN and_CC quality_NN improvement_NN techniques_NNS are_VBP not_RB without_IN relevance_NN to_TO the_DT HGP_NP ._SENT It_PP is_VBZ well_RB known_VBN that_IN the_DT mouse_NN genome_NN database_NN has_VBZ been_VBN contaminated_VBN with_IN entries_NNS of_IN the_DT rat_NN genome_NN and_CC that_IN the_DT specification_NN of_IN 5_CD '_'' to_TO 3_CD '_POS polarity_NN of_IN a_DT gene_NN sequence_NN has_VBZ been_VBN found_VBN to_TO be_VB inverted_VBN ._SENT ,_, ,_, And_CC these_DT are_VBP only_RB some_DT of_IN the_DT known_VBN errors_NNS in_IN a_DT very_RB large_JJ effort_NN ._SENT These_DT sources_NNS of_IN error_NN can_MD be_VB reduced_VBN ,_, as_IN they_PP have_VBP in_IN many_JJ industries_NNS ,_, by_IN the_DT application_NN of_IN increased_VBN process_NN automation_NN and_CC automated_JJ interception_NN of_IN human_JJ error_NN before_IN it_PP becomes_VBZ consequential_JJ ._SENT The_DT architectures_NNS of_IN clinical_JJ order_NN entry_NN systems_NNS ,_, designed_VBN for_IN complex_JJ clinical_JJ enterprises_NNS to_TO prevent_VB erroneous_JJ and_CC dangerous_JJ clinical_JJ behavior_NN ,_, can_MD inform_VB the_DT design_NN of_IN genome_NN sequencing_VBG and_CC expression_NN profiling_VBG processes_NNS to_TO prevent_VB the_DT kind_NN of_IN errors_NNS we_PP are_VBP already_RB finding_VBG in_IN genomic_JJ databases_NNS ._SENT It_PP is_VBZ well_RB known_VBN that_IN the_DT noise_NN in_IN clinical_JJ measurements_NNS leads_VBZ to_TO erroneous_JJ decision_NN making_NN ._SENT The_DT archetypal_JJ example_NN is_VBZ in_IN the_DT intensive_JJ care_NN unit_NN ,_, where_WRB multiple_JJ physiologic_NN monitors_VBZ each_DT has_VBZ its_PP$ own_JJ alarm_NN module_NN ._SENT Because_IN of_IN the_DT noisy_JJ nature_NN of_IN the_DT biological_JJ signals_NNS that_WDT are_VBP monitored_VBN ,_, the_DT alarms_NNS are_VBP ignored_VBN or_CC switched_VBN off_RP because_IN of_IN their_PP$ high_JJ false-positive_JJ rate_NN ._SENT The_DT noisy_JJ nature_NN of_IN the_DT monitored_VBN signals_NNS thus_RB has_VBZ a_DT significant_JJ impact_NN on_IN the_DT provision_NN of_IN care_NN and_CC the_DT decision-making_NN ability_NN of_IN care_NN providers_NNS who_WP are_VBP working_VBG under_IN conditions_NNS of_IN uncertainty_NN and_CC data_NN overload_NN ._SENT Similar_JJ noise_NN considerations_NNS arise_VBP in_IN genomics_NNS ._SENT For_IN example_NN ,_, with_IN gene_NN microarrays_NNS ,_, we_PP can_MD measure_VB the_DT expression_NN of_IN tens_NNS of_IN thousands_NNS of_IN genes_NNS at_IN a_DT time_NN ._SENT There_EX are_VBP several_JJ sources_NNS of_IN noise_NN in_IN these_DT measurements_NNS :_: within_IN a_DT microarray_NN ,_, across_IN microarrays_NNS ,_, and_CC from_IN the_DT intrinsic_JJ variability_NN of_IN the_DT biological_JJ systems_NNS being_VBG measured_VBN ._SENT Yet_RB in_IN 1999_CD ,_, several_JJ reports_NNS ,_, which_WDT appeared_VBD in_IN scientific_JJ journals_NNS of_IN the_DT first_JJ rank_NN ,_, included_VBD changes_NNS in_IN expression_NN so_RB small_JJ as_RB to_TO be_VB indistinguishable_JJ from_IN noise_NN ._SENT Such_JJ changes_NNS are_VBP ,_, in_IN essence_NN ,_, a_DT false-positive_JJ result_NN ._SENT These_DT false_JJ positives_NNS are_VBP potentially_RB extremely_RB costly_JJ ._SENT A_DT biological_JJ researcher_NN might_MD decide_VB to_TO invest_VB several_JJ months_NNS investigating_VBG a_DT gene_NN 's_POS regulation_NN because_IN a_DT microarray_NN experiment_NN showed_VBD it_PP to_TO be_VB increased_VBN or_CC decreased_VBN under_IN a_DT particular_JJ set_NN of_IN conditions_NNS ._SENT In_IN clinical_JJ informatics_NNS there_EX is_VBZ a_DT rich_JJ literature_NN of_IN the_DT techniques_NNS that_WDT can_MD be_VB used_VBN to_TO identify_VB false_JJ positives_NNS and_CC reduce_VBP noise_NN (_( e.g._FW ,_, filtering_VBG ,_, signal_VB fusion_NN ,_, ,_, ,_, ,_, )_) ._SENT Many_JJ of_IN these_DT techniques_NNS are_VBP transferable_JJ to_TO the_DT genomic_JJ domain_NN ._SENT In_IN 1997_CD ,_, the_DT Institute_NP of_IN Medicine_NP reported_VBD significant_JJ lacunae_NNS in_IN both_DT technology_NN and_CC policy_NN in_IN protecting_VBG confidential_JJ patient_JJ data_NNS ._SENT Among_IN the_DT problems_NNS of_IN greatest_JJS concern_NN that_WDT were_VBD emphasized_VBN by_IN this_DT report_NN were_VBD the_DT relatively_RB unrestricted_JJ access_NN by_IN third_JJ parties_NNS to_TO these_DT data_NNS for_IN secondary_JJ uses_NNS and_CC the_DT inadequacy_NN of_IN the_DT anonymization_NN process_NN (_( in_IN both_DT practice_NN and_CC theory_NN ,_, )_) ._SENT Subsequently_RB ,_, the_DT clinical_JJ informatics_NN community_NN has_VBZ developed_VBN several_JJ model_NN confidentiality_NN policies_NNS and_CC cryptographic_JJ identification_NN systems_NNS ._SENT As_IN the_DT fruits_NNS of_IN the_DT HGP_NP are_VBP translated_VBN first_RB into_IN clinical_JJ research_NN protocols_NNS and_CC then_RB into_IN clinical_JJ practice_NN ,_, personally_RB identifiable_JJ genomic_JJ data_NNS will_MD find_VB their_PP$ way_NN into_IN some_DT form_NN of_IN information_NN system_NN ._SENT The_DT challenges_NNS posed_VBD to_TO the_DT security_NN and_CC privacy_NN of_IN such_JJ data_NNS will_MD dwarf_VB any_DT encountered_VBN to_TO date_VB with_IN conventional_JJ clinical_JJ data_NNS ._SENT The_DT reasons_NNS are_VBP twofold_JJ :_: First_JJ ,_, genomic_JJ information_NN is_VBZ likely_JJ to_TO be_VB much_RB more_RBR predictive_JJ of_IN current_JJ and_CC future_JJ health_NN status_NN than_IN most_JJS clinical_JJ measurements_NNS ._SENT Second_RB ,_, with_IN very_RB few_JJ exceptions_NNS ,_, an_DT individual_NN 's_POS genome_NN is_VBZ uniquely_RB identifying_VBG ._SENT This_DT identifiability_NN is_VBZ much_RB more_RBR reliable_JJ ,_, persistent_JJ ,_, and_CC specific_JJ than_IN typically_RB cited_VBN identifiers_NNS ,_, including_VBG a_DT person_NN 's_POS name_NN ,_, social_JJ security_NN number_NN ,_, date_NN of_IN birth_NN ,_, and_CC address_NN ._SENT At_IN the_DT very_RB least_JJS ,_, the_DT architects_NNS of_IN information_NN systems_NNS storing_VBG genetic_JJ data_NNS should_MD learn_VB from_IN all_PDT the_DT mistakes_NNS of_IN and_CC designs_NNS developed_VBN for_IN the_DT security_NN architectures_NNS and_CC privacy_NN policies_NNS of_IN conventional_JJ clinical_JJ information_NN systems_NNS ._SENT Conversely_RB ,_, the_DT extreme_JJ concerns_NNS posed_VBN by_IN the_DT storage_NN of_IN personal_JJ genetic_JJ data_NNS is_VBZ likely_JJ to_TO generate_VB new_JJ policies_NNS and_CC security_NN architectures_NNS that_WDT will_MD enhance_VB the_DT confidentiality_NN of_IN clinical_JJ information_NN systems_NNS ._SENT Moreover_RB ,_, when_WRB personal_JJ genetic_JJ data_NNS becomes_VBZ incorporated_VBN into_IN routine_JJ medical_JJ practice_NN ,_, the_DT safeguards_NNS for_IN the_DT confidentiality_NN of_IN the_DT medical_JJ record_NN will_MD be_VB crucial_JJ to_TO the_DT confidentiality_NN of_IN the_DT genetic_JJ data_NNS referenced_VBN there_RB ._SENT "_'' Getting_VBG the_DT data_NNS in_IN "_`` has_VBZ often_RB been_VBN cited_VBN by_IN authorities_NNS in_IN clinical_JJ informatics_NNS as_IN being_VBG among_IN the_DT most_RBS difficult_JJ challenges_NNS in_IN successfully_RB deploying_VBG clinical_JJ information_NN systems_NNS ._SENT In_IN particular_JJ ,_, the_DT costs_NNS of_IN acquiring_VBG detailed_JJ and_CC structured_JJ data_NNS from_IN the_DT clinical_JJ care_NN process_NN have_VBP been_VBN daunting_VBG ._SENT Voice_NN and_CC handwriting_NN recognition_NN information_NN systems_NNS have_VBP not_RB been_VBN broadly_RB adopted_VBN ,_, because_IN of_IN a_DT variety_NN of_IN performance_NN and_CC usability_NN issues_NNS ._SENT The_DT cost_NN and_CC practicability_NN issues_NNS will_MD continue_VB to_TO present_VB obstacles_NNS to_TO clinical_JJ information_NN system_NN utility_NN and_CC deployment_NN until_IN better_JJR solutions_NNS are_VBP arrived_VBN at_IN ._SENT In_IN contrast_NN ,_, the_DT HGP_NP has_VBZ managed_VBN to_TO achieve_VB significant_JJ economies_NNS of_IN scale_NN in_IN sequencing_VBG technology_NN ._SENT Gene_NN microarrays_NNS alone_RB have_VBP dropped_VBN in_IN cost_NN by_IN a_DT factor_NN of_IN two_CD in_IN just_RB the_DT last_JJ year_NN ._SENT Here_RB again_RB ,_, once_IN genomic_JJ investigators_NNS attempt_VBP to_TO bridge_VB the_DT gulf_NN from_IN purely_RB genomic_JJ data_NNS sets_VBZ to_TO phenotypically_RB (_( i.e._FW ,_, clinically_RB )_) annotated_VBD data_NNS sets_NNS ,_, they_PP will_MD be_VB confronted_VBN with_IN the_DT same_JJ challenges_NNS of_IN clinically_RB oriented_VBN ,_, codified_VBN data_NNS acquisition_NN ._SENT The_DT questions_NNS of_IN which_WDT user_NN interfaces_NNS are_VBP the_DT most_JJS cost_NN efficient_JJ ,_, reliable_JJ ,_, and_CC generalizable_JJ to_TO multiple_JJ clinical_JJ domains_NNS are_VBP among_IN the_DT implementation_NN and_CC design_NN challenges_NNS that_IN they_PP will_MD face_VB ._SENT Although_IN they_PP have_VBP yet_RB to_TO arrive_VB at_IN definitively_RB successful_JJ answers_NNS ,_, clinical_JJ informaticians_NNS have_VBP already_RB completed_VBN several_JJ decades_NNS worth_JJ of_IN engineering_NN and_CC ethnographic_JJ studies_NNS addressing_VBG the_DT very_RB same_JJ questions_NNS ._SENT The_DT first_JJ rough_JJ draft_NN of_IN the_DT human_JJ genome_NN was_VBD reported_VBN to_TO have_VB been_VBN completed_VBN in_IN May_NP of_IN this_DT year_NN ._SENT It_PP is_VBZ likely_JJ that_IN a_DT complete_JJ ,_, high-quality_JJ human_JJ DNA_NN reference_NN sequence_NN will_MD be_VB available_JJ by_IN 2003_CD ._SENT Yet_RB the_DT function_NN of_IN the_DT vast_JJ majority_NN of_IN the_DT genes_NNS in_IN the_DT human_JJ genome_NN will_MD be_VB unknown_JJ ._SENT The_DT minority_NN of_IN genes_NNS with_IN documented_VBN function_NN are_VBP likely_JJ to_TO have_VB many_JJ more_JJR functions_NNS and_CC interactions_NNS that_WDT are_VBP unknown_JJ ._SENT Consequently_RB ,_, one_CD of_IN the_DT primary_JJ applications_NNS of_IN information_NN technologies_NNS in_IN genomics_NNS is_VBZ the_DT application_NN of_IN machine_NN learning_VBG techniques_NNS to_TO determine_VB how_WRB genes_NNS are_VBP functionally_RB interdependent_JJ and_CC how_WRB these_DT interdependencies_NNS are_VBP reflected_VBN in_IN the_DT biological_JJ and_CC clinical_JJ behavior_NN of_IN the_DT system_NN in_IN which_WDT they_PP operate_VBP ._SENT ,_, Many_JJ of_IN these_DT machine_NN learning_VBG techniques_NNS were_VBD previously_RB applied_VBN to_TO the_DT task_NN of_IN extracting_VBG knowledge_NN from_IN clinical_JJ databases_NNS ,_, and_CC some_DT were_VBD even_RB developed_VBN first_JJ in_IN the_DT clinical_JJ domain_NN ._SENT ,_, ,_, ,_, ,_, ,_, ,_, ,_, ,_, To_TO be_VB sure_JJ ,_, the_DT genomic_JJ era_NN has_VBZ challenged_VBN these_DT machine_NN learning_VBG techniques_NNS to_TO the_DT extreme_NN ,_, because_IN of_IN the_DT high_JJ dimensionality_NN of_IN data_NNS sets_VBZ (_( e.g._FW ,_, tens_NNS of_IN thousands_NNS of_IN measurements_NNS per_IN experiment_NN )_) and_CC the_DT relatively_RB few_JJ cases_NNS and_CC experiments_NNS from_IN which_WDT investigators_NNS are_VBP attempting_VBG to_TO glean_VB knowledge_NN ._SENT Without_IN being_VBG exhaustive_JJ ,_, this_DT brief_JJ review_NN suggests_VBZ the_DT multiple_JJ points_NNS of_IN commonality_NN between_IN the_DT genomic_JJ and_CC clinical_JJ strands_NNS of_IN the_DT biomedical_JJ informatics_NN research_NN agenda_NN ._SENT It_PP also_RB suggests_VBZ that_IN the_DT training_NN of_IN investigators_NNS in_IN informatics_NNS should_MD include_VB a_DT set_NN of_IN core_JJ competencies_NNS that_IN at_IN least_JJS cover_VB these_DT common_JJ points_NNS ._SENT In_IN this_DT fashion_NN ,_, the_DT joint_JJ research_NN agenda_NN might_MD be_VB well_RB served_VBN to_TO the_DT mutual_JJ benefit_NN of_IN biomedical_JJ science_NN and_CC clinical_JJ care_NN ._SENT The_DT Stanford_NP Medical_NP Informatics_NNS educational_JJ program_NN ,_, described_VBN in_IN this_DT issue_NN ,_, illustrates_VBZ this_DT benefit_NN ._SENT 